1.46
0.31 (26.96%)
| Previous Close | 1.15 |
| Open | 1.14 |
| Volume | 1,583,165 |
| Avg. Volume (3M) | 187,771 |
| Market Cap | 14,133,187 |
| Price / Sales | 0.130 |
| Price / Book | 0.230 |
| 52 Weeks Range |
| Profit Margin | -294.05% |
| Operating Margin (TTM) | -131.10% |
| Diluted EPS (TTM) | -53.53 |
| Quarterly Revenue Growth (YOY) | -26.40% |
| Total Debt/Equity (MRQ) | 38.21% |
| Current Ratio (MRQ) | 1.70 |
| Operating Cash Flow (TTM) | -43.55 M |
| Levered Free Cash Flow (TTM) | 4.19 M |
| Return on Assets (TTM) | -30.70% |
| Return on Equity (TTM) | -127.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Bionano Genomics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -1.13 |
|
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 0.06% |
| % Held by Institutions | 9.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Carret Asset Management, Llc | 31 Dec 2025 | 44,100 |
| R Squared Ltd | 31 Dec 2025 | 13,771 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies |
| 12 Jan 2026 | Announcement | Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |